These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37541591)

  • 1. Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.
    Alenazy FO; Harbi MH; Kavanagh DP; Price J; Brady P; Hargreaves O; Harrison P; Slater A; Tiwari A; Nicolson PLR; Connolly DL; Kirchhof P; Kalia N; Jandrot-Perrus M; Mangin PH; Watson SP; Thomas MR
    J Thromb Haemost; 2023 Nov; 21(11):3236-3251. PubMed ID: 37541591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
    Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs.
    Harbi MH; Smith CW; Alenazy FO; Nicolson PLR; Tiwari A; Watson SP; Thomas MR
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L; Alves VL; Phillips DR
    Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease.
    Slater A; Khattak S; Thomas MR
    Eur Heart J Cardiovasc Pharmacother; 2024 Aug; 10(5):465-473. PubMed ID: 38453424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study.
    Dalby M; Montalescot G; Bal dit Sollier C; Vicaut E; Soulat T; Collet JP; Choussat R; Gallois V; Drobinski G; Drouet L; Thomas D
    J Am Coll Cardiol; 2004 Jan; 43(2):162-8. PubMed ID: 14736431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
    Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
    J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of aspirin on platelet desaggregation induced by SR121566, a potent GP-IIb/IIIa antagonist.
    Savi P; Bernat A; Lalé A; Roque C; Zamboni G; Herbert JM
    Platelets; 2000 Feb; 11(1):43-8. PubMed ID: 10938881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
    Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
    Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
    Galli M; Franchi F; Rollini F; Been L; Jaoude PA; Rivas A; Zhou X; Jia S; Maaliki N; Lee CH; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Geisler T; Jennings LK; Bass TA; Angiolillo DJ
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):728-737. PubMed ID: 35353154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet therapy in acute coronary syndromes.
    Barker CM; Price MJ
    Curr Cardiol Rep; 2008 Jul; 10(4):327-33. PubMed ID: 18611368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glenzocimab: A GPVI (Glycoprotein VI)-Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke.
    Wichaiyo S; Parichatikanond W; Rattanavipanon W
    Stroke; 2022 Nov; 53(11):3506-3513. PubMed ID: 36128904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
    Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential Inhibition of Human Atherosclerotic Plaque-Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies: Functional and Imaging Studies.
    Jamasbi J; Megens RT; Bianchini M; Münch G; Ungerer M; Faussner A; Sherman S; Walker A; Goyal P; Jung S; Brandl R; Weber C; Lorenz R; Farndale R; Elia N; Siess W
    J Am Coll Cardiol; 2015 Jun; 65(22):2404-15. PubMed ID: 26046734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel antiplatelet targets in the treatment of acute coronary syndromes.
    Alenazy FO; Thomas MR
    Platelets; 2021 Jan; 32(1):15-28. PubMed ID: 32529932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
    Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
    Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple antiplatelet therapy in acute coronary syndromes.
    Valgimigli M; Minarelli M
    Drugs; 2011 Sep; 71(13):1703-19. PubMed ID: 21902293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.